Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172829 | 0.93 | CYP19A1 (0.42) | CYP19A1UGT1A4PDE4DPOLBALDH1A1 | |
| SCHEMBL10701617 | 0.89 | CYP19A1 (0.39) | CYP19A1UGT1A4PDE4DPOLBTSHR | |
| SCHEMBL24454561 | 0.83 | RAPGEF4 (0.42) | CYP19A1UGT1A4PDE4DKIF11PGK1 | |
| SCHEMBL15709374 | 0.81 | CYP19A1 (0.38) | GABRA1GABRB2CYP19A1UGT1A4PDE4D | |
| SCHEMBL25583303 | 0.81 | GABRA1 (0.67) | GABRA1GABRB2CYP19A1UGT1A4PDE4D | |
| SCHEMBL1655430 | 0.81 | GABRA1 (0.55) | GABRA1GABRB2POLBRXRARXRB | |
| SCHEMBL21902424 | 0.80 | PGK1 (0.39) | CYP19A1UGT1A4PDE4DPGK1PGK2 | |
| SCHEMBL22186425 | 0.79 | ALDH1A1 (0.48) | CYP19A1UGT1A4PDE4DPOLBTSHR | |
| SCHEMBL22915820 | 0.79 | ALDH1A1 (0.46) | GABRA1GABRB2CYP19A1UGT1A4PDE4D | |
| SCHEMBL305812 | 0.79 | CYP19A1 (0.34) | CYP19A1UGT1A4PDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458104-B2 | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ | PHENEX PHARMACEUTICALS AG (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8946446-B2 | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | GABRA1 583/4885GABRB2 267/4885CYP19A1 2867/4885 |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | RORA, RORB, RORC | GABRA1 261/4885GABRB2 342/4885CYP19A1 691/4885 |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | RORA, RORB, RORC | GABRA1 256/4885GABRB2 313/4885CYP19A1 754/4885 |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | GABRA1 256/4885GABRB2 249/4885CYP19A1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.